Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UK Royal Society targets £20m for early-stage tech support

This article was originally published in Clinica

Executive Summary

The UK's Royal Society has launched an Enterprise Fund (RSEF) aimed at supporting innovation "by investing in early-stage business opportunities founded on outstanding technology". The fund, which is said to have already attracted donations amounting to “several million pounds", will focus on what the Royal Society sees as a gap in early-stage investments in the £0.25-2m ($0.37-3m) range. Marking its 350th anniversary campaign, it is aiming to capitalise the fund initially to around £20m. The Society sees "three key gaps within the UK innovation environment", namely: a funding gap for early-stage investments, in the said range; a "preparedness gap", with early-stage science-based projects "not always ready to go to the market for financing"; and a research area gap, with "comparatively poor funding" of non-medical research fields.

You may also be interested in...



Zur Rose Calls For Swiss Online Liberalization To Manage Coronavirus OTC Demand

Europe's largest online pharmacy is calling for online sales of OTC medicines to be allowed in its home market Switzerland, to increase the supply of crucial products to help people manage the symptoms of COVID-19, such as headaches, fever, diarrhoea, coughs, colds or nausea.

UK IVDs Firms Working Flat Out On COVID-19 Tests, As Govt Promises Test Capacity Increase

Confusion is rife over low UK testing levels to confirm COVID-19 in health care staff and patients, and comparisons with measures taken in similar-sized economies have been unfavorable. Diagnostics manufacturers are not to blame, says the industry.

Coronavirus Update: Novartis Targets COVID-19 Cytokine Storm With Jakavi

Novartis's Jakavi joins the likes of Roche's Actemra in targeting the life-threatening immune reaction which is killing acutely ill COVID-19 patients.

Topics

UsernamePublicRestriction

Register

MT041234

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel